Compare MUJ & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MUJ | RGNX |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 631.8M | 661.2M |
| IPO Year | N/A | 2015 |
| Metric | MUJ | RGNX |
|---|---|---|
| Price | $11.90 | $13.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $30.29 |
| AVG Volume (30 Days) | 108.0K | ★ 619.3K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $161,318,000.00 |
| Revenue This Year | N/A | $198.02 |
| Revenue Next Year | N/A | $2.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 91.30 |
| 52 Week Low | $9.74 | $5.04 |
| 52 Week High | $11.70 | $13.93 |
| Indicator | MUJ | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 63.87 | 63.59 |
| Support Level | $11.62 | $10.76 |
| Resistance Level | $11.95 | $13.80 |
| Average True Range (ATR) | 0.08 | 0.79 |
| MACD | -0.00 | 0.19 |
| Stochastic Oscillator | 81.82 | 80.81 |
BlackRock MuniHoldings New Jersey Quality Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund mainly invests in long-term, investment-grade municipal obligations exempt from U.S federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and New Jersey personal income taxes, with remaining maturities of one year or more at the time of investment. The rest of its managed assets can be invested in securities that are rated below investment grade (or similar instruments), or invested directly in securities or synthetically through the use of derivatives.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.